T2 Biosystems Earns Neutral Rating from Analysts at Goldman Sachs (TTOO)
Equities researchers at Goldman Sachs started coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a research report issued on Tuesday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating and a $25.00 price target on the stock. Goldman Sachs’ target price suggests a potential upside of 7.71% from the company’s current price.
T2 Biosystems (NASDAQ:TTOO) traded down 10.19% during mid-day trading on Tuesday, hitting $20.844. 93,639 shares of the company’s stock traded hands. T2 Biosystems has a 52-week low of $13.40 and a 52-week high of $24.50. The stock’s 50-day moving average is $18.94 and its 200-day moving average is $18.94. The company’s market cap is $400.1 million.
Separately, analysts at Leerink Swann initiated coverage on shares of T2 Biosystems in a research note on Tuesday. They set a “market perform” rating and a $23.50 price target on the stock.
T2 Biosystems, Inc is an in vitro diagnostics company. The Company that has developed a technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.